Speaking with StarBizWeek, LYC chief operating officer Ahmad Rafique Mat Tahir, a former investment banker and private equity professional, says LYC has a few core platforms that it is building on and the focus remains on the specialist areas of healthcare that promise higher margins.足球分析师（www.99cx.vip）是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。足球分析师上足球分析专家数据更新最快。足球分析师开放皇冠官方会员注册、皇冠官方代理开户等业务。
LYC Healthcare Bhd, known for its upmarket mother and child centres, has been in the news recently for announcing a number of new acquisitions (see table).
The new businesses the company is buying range from nutraceuticals, dental services, aesthetics and specialist clinics.
But can ACE Market-listed LYC, with a market capitalisation of a mere RM102mil afford the new purchases? And will it be able to digest all of them? More importantly, what is the focus of the group going forward?
Speaking with StarBizWeek, LYC chief operating officer Ahmad Rafique Mat Tahir, a former investment banker and private equity professional, says LYC has a few core platforms that it is building on and the focus remains on the specialist areas of healthcare that promise higher margins.
“Compared with the other listed healthcare companies, we are small and agile.
“We are looking at what we call ‘healthcare 2.0’ unlike traditional healthcare companies where the focus tends to be on building hospitals. The gestation period for this can be quite long as compared with specialist areas of healthcare. There are also synergies between all the assets we are acquiring,” Rafique explains.,
Of the different platforms at LYC today, the main one is its mother and child centre. Under this, the group operates four centres with a total capacity of 193 rooms, including a recently opened one in Johor Baru, to cater to both Johorians and Singaporeans.
It offers services such as confinement, postnatal and postpartum care. Under this segment, the group also operates an 80-pax child day-care service.
“Our second platform is LYC Medicare (Singapore) Pte Ltd, which is the entity we are planning to list on the Catalist Board of the Singapore Exchange (SGX).
“It groups specialist clinics and a nutraceutical business, which is in the supply chain of supplements and pharmaceutical-based products,” he shares.
Ahead of LYC Medicare’s impending initial public offering (IPO), Kenanga Investment Bank Bhd had been roped in as a pre-IPO anchor.
The investment bank, via Kenanga Investors Bhd, took up a 25% stake in the Singapore unit, paying S$12.9mil (RM41.33mil) for the block.
Apart from this, LYC is also buying the remaining 49% stakes it does not hold in two Singapore-based companies for a combined value of S$17.26mil (RM55.25mil), which will be done via a combination of cash and shares.